Allakos Inc. (ALLK) has announced positive phase II results from two additional chronic urticaria cohorts - patients with cholinergic urticaria and symptomatic dermographism.
In the Cholinergic Urticaria Cohort, 9 of 11 patients achieved a response, and in the Symptomatic dermographism cohort, 7 of 10 patients achieved a response.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com